Research Partnership launches new patient Living with Psoriatic Arthritis (PsA) 2019 EU report
Living with Psoriatic Arthritis is new a report conducted amongst 265 patients in France, Germany, Italy, Spain and UK. The report is based on the findings from 30-minute quantitative online and qualitative telephone interviews with patients. It will provide an update on the existing Living with PsA report published in 2016 and will be available to purchase in October 2019.
Research Partnership publishes new patient Living with Ankylosing Spondylitis & nr-axSpA EU & US 2019 reports
Living with Ankylosing Spondylitis (AS) & nr-AxSpA are reports based on quantitative studies conducted online in the 5EU and US. The AS 5EU report comprises of interviews with 385 patients in France, Germany, Italy, Spain and UK, while the AS US report is based on a study of 136 patients. The Living with nr-AxSpA report comprises of interviews with a total of 78 patients in the 5EU and the US. All of the studies consist of 30-minute quantitative online interviews and for the AS studies 30 minute qualitative tele-depth interviews. The reports are available to purchase in the following formats: AS (5EU), AS (US) and nr-AxSpA (5EU & US).
Research Partnership launches new patient Living with Ankylosing Spondylitis EU and US 2019 report
Living with ankylosing spondylitis (AS) is a quantitative study conducted online amongst give the total number 365 patients diagnosed with AS in the 5 EU; up to 100 of these will be classified as likely nr-AxSpA in the 5 EU markets (France, Germany, Italy, Spain, UK). In the US, the study is conducted with 105 AS patients and 30 nr-AxSpA patients. The report consists of quantitative 30 minute quantitative online interviews and qualitative tele-depth interviews, and will be published in the 1st quarter 2019.
The impact on patient outcomes in the treatment of non-radiographic axial spondyloarthritis
The Therapy Watch nr-axial SpA monthly study was launched in July 2014 among a panel of 200 EU5 rheumatologists to provide insight into the characteristics of nr-axSpA patients, existing treatment strategies and potential barriers to prescribing.
The Therapy Watch nr-axial SpA monthly study was launched in July 2014 among a panel of 200 EU5 rheumatologists to provide insight into the characteristics of nr-axSpA patients, existing treatment strategies and potential barriers to prescribing.Axial spondyloarthritis (axSpA) is still a relatively new term in rheumatology and the recent nomenclature separating axial vs. peripheral, and radiographic and non-radiographic spondyloarthritis has changed the perspective of ankylosing spondylitis (AS) by switching the focus towards earlier diagnosis and treatment of the disease.